Evidence map›Paper›PMID 36034180›Full record

ArticleBiochemical engineering journal2022

Engineered multivalent self-assembled binder protein against SARS-CoV-2 RBD.

Dustin Britton, Kamia Punia, Farbod Mahmoudinobar, Takuya Tada, Xunqing Jiang, P Douglas Renfrew, Richard Bonneau, Nathaniel R Landau, Xiang-Peng Kong, Jin Kim Montclare

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemical engineering journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dustin BrittonDepartment of Chemical and Biomolecular Engineering, New York University Tandon School of Engineering, Brooklyn, New York 11201, USA.
Kamia PuniaDepartment of Chemical and Biomolecular Engineering, New York University Tandon School of Engineering, Brooklyn, New York 11201, USA.
Farbod MahmoudinobarDepartment of Chemical and Biomolecular Engineering, New York University Tandon School of Engineering, Brooklyn, New York 11201, USA.
Takuya TadaDepartment of Microbiology, NYU, Grossman School of Medicine, New York, New York 10016, USA.
Xunqing JiangDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, New York 10016, USA.
P Douglas RenfrewCenter for Computational Biology, Flatiron Institute, New York, New York 10010, USA.
Richard BonneauCenter for Computational Biology, Flatiron Institute, New York, New York 10010, USA.
Nathaniel R LandauDepartment of Microbiology, NYU, Grossman School of Medicine, New York, New York 10016, USA.
Xiang-Peng KongDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, New York 10016, USA.
Jin Kim MontclareDepartment of Chemical and Biomolecular Engineering, New York University Tandon School of Engineering, Brooklyn, New York 11201, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic since December 2019, and with it, a push for innovations in rapid testing and neutralizing antibody treatments in an effort to solve the spread and fatality of the disease. One such solution to both of these prevailing issues is targeting the interaction of SARS-CoV-2 spike receptor binding domain (RBD) with the human angiotensin-converting enzyme 2 (ACE2) receptor protein. Structural studies have shown that the N-terminal alpha-helix comprised of the first 23 residues of ACE2 plays an important role in this interaction. Where it is typical to design a binding domain to fit a target, we have engineered a protein that relies on multivalency rather than the sensitivity of a monomeric ligand to provide avidity to its target by fusing the N-terminal helix of ACE2 to the coiled-coil domain of the cartilage oligomeric matrix protein. The resulting ACE-MAP is able to bind to the SARS-CoV-2 RBD with improved binding affinity, is expressible in

Indexed as

Antibody-mimicDiagnosticProtein engineeringSARS-CoV-2Therapeutic

Identifiers

PMID36034180
PMCPMC9396458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.